ライフサイエンスコーパス: chemosensitive

1 inclusion of bexarotene, the cells remained chemosensitive.

2 found that 34% (61 of 178) of GC units were chemosensitive.

3 rons with this anatomical specialization are chemosensitive.

4 also respond to local glutamate and thus be chemosensitive.

5 nsory integration centers and are themselves chemosensitive.

6 ned 83.3% of the cases as chemorefractory or chemosensitive.

7 ignancies, originate in utero and are highly chemosensitive.

8 er of thermosensitive mitral cells were also chemosensitive.

9 ndependent growth, and rendered glioma cells chemosensitive.

10 the brainstem chemoreceptor areas are highly chemosensitive.

11 Ninety-four patients with either chemosensitive (50 patients) or chemoresistant (44 patie

12 ant ABCB1(high) (A498, Caki-1) compared with chemosensitive ABCB1(low) (ACHN, normal human proximal c

13 me treatment on progression in patients with chemosensitive advanced colorectal cancer.

14 the muscle interstitium where they stimulate chemosensitive afferent nerves that reflexly increase ef

15 differentially affects mechanosensitive and chemosensitive afferent pathways.

16 ly evoked plantar flexion, where only muscle chemosensitive afferents were likely to be stimulated, B

17 solidation therapy for PTCL patients who are chemosensitive after induction chemotherapy.

18 nting number of competing nuclei proposed as chemosensitive along with an ever increasing list of pot

19 was significantly higher than that noted in chemosensitive AML (P=0.018).

20 atient-derived xenografts to generate paired chemosensitive and chemoresistant cancers.

21 e-dependently inhibited the proliferation of chemosensitive and chemoresistant glioma cells but did n

22 augmented chemotherapeutic efficacy in both chemosensitive and chemoresistant models of small cell l

23 itously released in high abundance from both chemosensitive and chemoresistant ovarian cancer cells v

24 nomycin-induced PARC down-regulation in both chemosensitive and chemoresistant ovarian cancer cells.

25 Models were established from both chemosensitive and chemoresistant tumors, and nearly 30%

26 n results from ischemic episodes that excite chemosensitive and mechanoreceptive receptors in the hea

27 rs with oligodendroglial differentiation are chemosensitive and this correlates with allelic loss of

28 both RTN and pfRG neurons are intrinsically chemosensitive and tonically firing neurons whose respir

29 x vivo in tissue culture are also relatively chemosensitive and undergo apoptotic death in response t

30 ical astrocytes, astrocytes of the brainstem chemosensitive area(s) possess signaling properties that

31 urface of the brainstem (central respiratory chemosensitive area) respond to physiological decreases

32 the retrotrapezoid nucleus (RTN), a central chemosensitive area, and the rostral ventrolateral medul

33 cells were not found in any of the putative chemosensitive areas.

34 ellular PCO2/[H(+)] with Ca(2+) responses in chemosensitive astrocytes remain unknown.

35 lthough Burkitt lymphoma cells are extremely chemosensitive, biologically targeted therapies should b

36 umab also prevented tumor growth in both the chemosensitive BL0440 and chemoresistant BL0269 models.

37 between neurones from the medullary raphe (a chemosensitive brain region) and hippocampus (a non-chem

38 ct the drive to breathe, we hypothesize that chemosensitive brain regions have adapted a means of pre

39 tzinger rhythm-generating complex and in the chemosensitive brainstem respiratory regions, thereby in

40 d nuclear p53 accumulation, and apoptosis in chemosensitive but not resistant OVCA cells.

41 ggressive disease-the condition is initially chemosensitive but then relapses with acquired chemoresi

42 Small-cell lung cancer (SCLC) is exquisitely chemosensitive, but few patients are cured by convention

43 Small cell lung cancer (SCLC) is initially chemosensitive, but rapidly relapses in a chemoresistant

44 en patients designated as chemorefractory or chemosensitive by using the baseline CNA classifier.

45 Interestingly, chemosensitive cancer cell lines (A2780 and PEO1) displa

46 The chemosensitive cancer cells could not survive glucose de

47 Chemosensitive carotid body glomus cells exhibited toll-

48 are associated with poor prognosis, even in chemosensitive cases.

49 nd higher P-glycoprotein expression than the chemosensitive cell lines MCF7-wt and MES-SA.

50 ye-filled neurons showed that ASIC-dependent chemosensitive cells (cells responding to pH 7.0) cluste

51 omponents of transduction to the identity of chemosensitive cells and chemosensitive nuclei.

52 Conversely, upregulation of MVP in chemosensitive cells does not confer increased drug resi

53 ytes, the star-shaped brain cells, are known chemosensitive cells in the respiratory system.

54 ar composition of the native KO2 channels in chemosensitive cells is important to understand the mech

55 e therapy to maintain a stable population of chemosensitive cells that can, in turn, suppress the gro

56 en by permitting a significant population of chemosensitive cells to survive so that they, in turn, s

57 surviving cells and a delay in the death of chemosensitive cells which outperforms the original bi-e

58 arwinian environment of a cancer, the fitter chemosensitive cells will ordinarily proliferate at the

59 Rat carotid body chemosensitive cells, and human neutrophils, were treate

60 cellular components and trigger apoptosis in chemosensitive cells.

61 K+ channel similar to that recorded in other chemosensitive cells.

62 idative phosphorylation (OXPHOS) compared to chemosensitive cells.

63 re upregulated in chemoresistant compared to chemosensitive cells.

64 ad favoring the expansion of rarer and unfit chemosensitive clones.

65 s offer the basis of methods for reversible, chemosensitive control of the interfacial organization o

66 fter cPGI but is more excitable and markedly chemosensitive (CS) with a pronounced enhancement of max

67 For relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL), co

68 One hundred fifty-three patients with chemosensitive disease after ICE (ifosfamide, carboplati

69 ion may be considered in young patients with chemosensitive disease and in newly diagnosed patients w

70 All patients presented with chemosensitive disease at transplantation.

71 Five of six patients (83.3%) with chemosensitive disease continue to be alive compared wit

72 at relapse from five patients with initially chemosensitive disease did not switch to a chemorefracto

73 Fourteen patients with chemosensitive disease evident on neuroimaging then rece

74 For those with chemosensitive disease the PFS and OS were 42% and 55%,

75 ized in patients with a high-risk and poorly chemosensitive disease to improve their PFS/OS (patient

76 1 year for patients with chemoresistant and chemosensitive disease were 75% and 25%, respectively (P

77 rates for patients with chemorefractory and chemosensitive disease were 80% and 87%, respectively (P

78 dministering HDT/ASCT to those patients with chemosensitive disease were reviewed.

79 A subgroup of patients with residual chemosensitive disease who attained complete remission a

80 We retrospectively analyzed patients with chemosensitive disease who underwent high-dose chemoradi

81 rs); median prior regimens, 6 (range, 3-12); chemosensitive disease, 6 (15%); bulk > 5 cm, 17 (range,

82 In select patients with chemosensitive disease, autologous stem cell transplanta

83 and was significantly better for those with chemosensitive disease, Hodgkin disease (HD), and low-gr

84 iled in five (28%) patients and 16 (89%) had chemosensitive disease.

85 tent of administering HDT/ASCT to those with chemosensitive disease.

86 mainly be effective in patients with poorly chemosensitive disease.

87 llowed by autologous stem cell transplant in chemosensitive disease.

88 gous transplant consolidation for those with chemosensitive disease.

89 esistant disease versus 33% of patients with chemosensitive disease; P = 0.005) and decreased overall

90 Forty-three patients (50.6%) had ICE-chemosensitive disease; there was no difference in the r

91 In conclusion, for relapsed chemosensitive DLBCL patients with residual PET/CT+ dise

92 a support ongoing application of auto-HCT in chemosensitive DLBCL.

93 mismatch repair (MMR) and the repair of the chemosensitive DNA lesion, O6-methylguanine (O6-MeG), by

94 ctivity in part by cholinergic activation of chemosensitive elements of the RTN.

95 xed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but

96 TATEMENT Most studies of taste buds view the chemosensitive excitable cells that express taste recept

97 CO2-chemosensitive firing responses using single-cell patch

98 ituximab (FCR) conditioning for relapsed and chemosensitive follicular lymphoma.

99 The molecular mechanisms that differentiate chemosensitive from chemorefractory disease are currentl

100 o identify genetic features that distinguish chemosensitive from chemorefractory disease, we examined

101 Hypothalamic tanycytes are chemosensitive glial cells that contact the cerebrospina

102 Although carotid chemosensitive glomus cells have been the most extensive

103 In carotid body chemosensitive glomus cells, activation of toll-like rec

104 dicate that there is severe loss of putative chemosensitive glutamatergic and serotonergic neurons as

105 Chemosensitive glutamatergic and serotonergic neurons lo

106 ity as well as an increase in the numbers of chemosensitive group III/IV muscle afferents as assessed

107 wever, the proliferation rate is low in many chemosensitive human cancers, and it is not clear how a

108 n medullary serotonergic neurones, which are chemosensitive in vitro.

109 nd cell lines derived from these tumours are chemosensitive in vitro.

110 atal day 12 (P12), when 5-HT neurones become chemosensitive in vitro.

111 e many neurons that make up this network are chemosensitive in vitro.

112 Exquisitely chemosensitive initially, small cell lung cancer (SCLC)

113 ow that hTRPA1 is an intrinsically cold- and chemosensitive ion channel.

114 Small cell lung cancer is a chemosensitive malignancy, yet long-term survival remain

115 tive strategy for patients with relapsed and chemosensitive mantle-cell lymphoma.

116 f the estrogen receptor alpha (ER)-positive, chemosensitive MCF7 breast cancer cell line to tumor nec

117 nding and suggesting mechanosensitive and/or chemosensitive mechanisms for upregulation.

118 n TRPA1 (hTRPA1-HEK), as well as a subset of chemosensitive mouse trigeminal neurons.

119 uli and the BAO-induced phenotypic switch in chemosensitive muscle afferents, potentially through reg

120 red mouse model develops rapidly progressive chemosensitive neuroblastoma and lacks clinically releva

121 ed whether reduction in PHOX2B expression in chemosensitive neuromedin-B (NMB) expressing neurons in

122 suggest that an important characteristic of chemosensitive neurones is an unusually large change of

123 its presence is not uniquely associated with chemosensitive neurones.

124 urons in deep versus superficial layers with chemosensitive neurons across all categories showing sim

125 in CO(2) /H(+) , has been shown to activate chemosensitive neurons and increase inspiratory activity

126 n involve direct H(+)-mediated activation of chemosensitive neurons and indirect modulation of chemos

127 sensitive neurons and indirect modulation of chemosensitive neurons by purinergic signalling.

128 here is significant evidence suggesting that chemosensitive neurons exist in other brainstem areas, i

129 (HCVR) and hypoxia (HVR); and (c) number of chemosensitive neurons in mice.

130 /H(+)-dependent drive to breathe produced by chemosensitive neurons in the retrotrapezoid nucleus (RT

131 Chemosensitive neurons in the retrotrapezoid nucleus (RT

132 Isoflurane also increased firing rate of RTN chemosensitive neurons in urethane-anesthetized rats, ag

133 o and the excitability of isolated pulmonary chemosensitive neurons in vitro, and this effect of PAR2

134 als are a probable marker of RTN; and 4) the chemosensitive neurons of RTN may provide a chemical dri

135 he main stimulus for breathing by activating chemosensitive neurons that control respiratory output.

136 onal brain slices (postnatal days 7-12), RTN chemosensitive neurons were silent at pH 7.55.

137 sensitivity of isolated rat vagal pulmonary chemosensitive neurons.

138 stimulation of Phox2b-lineage, putative CO2-chemosensitive neurons.

139 ing reduced CO2 -induced firing responses of chemosensitive neurons.

140 europil likely regulates the activity of RTN chemosensitive neurons; 2) the catecholaminergic, cholin

141 create 5-FdUMP resistant enzymes to protect chemosensitive normal cells and further understand mecha

142 also augmented action potential discharge in chemosensitive nTS neurons.

143 to the identity of chemosensitive cells and chemosensitive nuclei.

144 we show that CTCs from patients with either chemosensitive or chemorefractory SCLC are tumorigenic i

145 n effective option in lymphoma patients with chemosensitive or stable disease who experience disease

146 Patients were required to have chemosensitive or stable disease.

147 s of whether neurones were cultured from the chemosensitive or the non-chemosensitive region, pH(i) d

148 r processes in the RTN/Ppy region are either chemosensitive or they modulate chemosensitivity.

149 serotonergic neurones (most of which are not chemosensitive), or from the DeltapH(i)/DeltapH(o) of hi

150 ess visceral organs and are only temporarily chemosensitive, ovarian carcinoma is a deadly disease, w

151 lenge, increases calcium oscillations in the chemosensitive parafacial respiratory group (pFRG/RTN).

152 e extended these data to genetically perturb chemosensitive patient-derived xenograft (PDX) models of

153 re affected by a selection bias because only chemosensitive patients actually proceeded to AHCT, wher

154 r delaying development of drug resistance in chemosensitive patients represents another therapeutic s

155 tic responses, we perform genetic screens in chemosensitive PDX models to identify drivers of chemore

156 In chemosensitive PDX models, overexpression of either MYCN

157 cancer stem cells differentiated into their chemosensitive progeny, they lost tumor-initiating capac

158 to metabolic acidosis, the neurones from the chemosensitive region do not have a uniquely high Deltap

159 he perinatal pFRG and appears lateral to the chemosensitive region of adult RTN.

160 These glutamatergic neurons are located in a chemosensitive region of the ML and their projections ar

161 rons that presumably project directly to the chemosensitive region of the RTN.

162 nsitive brain region) and hippocampus (a non-chemosensitive region), we used BCECF to monitor pH(i) i

163 cultured from the chemosensitive or the non-chemosensitive region, pH(i) did not recover during any

164 gers the immediate release of ATP from three chemosensitive regions located on the ventral surface of

165 s reinforce past findings that patients with chemosensitive relapse are better candidates for high-do

166 of lenalidomide maintenance in patients with chemosensitive relapse of DLBCL not eligible for ASCT or

167 first CR, compared with 37% for patients in chemosensitive relapse, and 7% for chemoresistant patien

168 patients with relapsed disease, particularly chemosensitive relapse, are superior to those reported f

169 lapse rates within the first 3 years for the chemosensitive relapse, chemoresistant, and induction fa

170 lantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-c

171 y, similar to the outcomes for patients with chemosensitive relapsed disease.

172 The chemosensitive response of locus coeruleus (LC) neurones

173 gnals play a greater role in determining the chemosensitive response to changes in CO2/H+ than previo

174 Therefore, chemosensitive RTN neurons appear to be critically impor

175 urochemical phenotype previously defined for chemosensitive RTN neurons in vivo.

176 nt are less excitable, whereas glutamatergic chemosensitive RTN neurons, which are a key source of th

177 Deletion of KEAP1 switched a chemosensitive SCLC PDX model to become chemoresistant a

178 stic BM samples from primary refractory AML (chemosensitive) showed methylation of WIT-1.

179 roception and ARNA activation, which include chemosensitive stimuli during prolonged renal artery occ

180 roception and ARNA activation, which include chemosensitive stimuli during prolonged renal artery occ

181 to an increase in P(CO2)/[H+] (hypercapnia) chemosensitive structures located on the ventral surface

182 n even in seminoma and that seminoma is more chemosensitive than nonseminoma, a renewed clinical need

183 r, the widely accepted view that BAC is less chemosensitive than other NSCLCs is not clearly supporte

184 s cancer cells and why some cancers are more chemosensitive than others.

185 te when it was focally applied to the apical chemosensitive tips of receptor cells.

186 direct evidence that pre-LSCs are much less chemosensitive to existing chemotherapy drugs than leuke

187 er cells expressing MT1-MMP were selectively chemosensitive to ICT2588, whereas MCF7 cells that did n

188 l/ref aggressive B-cell non-Hodgkin lymphoma chemosensitive to salvage therapy with: (1) positron emi

189 rons in the midbrain of rats are also highly chemosensitive to small changes in CO2/pH and are closel

190 Patients with chemosensitive transformed lymphoma should be seriously

191 n tumor in children, is a radiosensitive and chemosensitive tumor.

192 o have high TSP as compared to patients with chemosensitive tumors (HR, 2.861; 95% CI, 1.256-6.515; P

193 OF REVIEW: Synovial sarcomas are regarded as chemosensitive tumors compared to other types of soft ti

194 Further trials in children with chemosensitive tumors, with minimal residual disease, ar

195 l tumors (TGCT) are considered a paradigm of chemosensitive tumors.

196 Pharmacological activation of chemosensitive vagal afferents with phenyl biguanide pro

197 The two subtypes of chemosensitive VMM neurones could be distinguished by ch

198 atients that entered CR after therapy (i.e., chemosensitive) were studied and only 10 (37%) of the di

199 ed carboplatin-induced apoptosis in the more chemosensitive WERI, but not the chemoresistant Y79 line

200 that epithelial ovarian cancer is moderately chemosensitive, what distinguishes it most from other me

201 aunorubicin resistant AML cells, relative to chemosensitive wildtype controls, HL-60 cells refractory

202 Small cell lung cancer was termed chemosensitive with the introduction of combination chem

203 relatively uncommon carcinomas is initially chemosensitive, with a high overall response rate to com